Cantargia AB CANTA
Valuation and Optionality hold this up; Moat is the soft spot.
| Moat | 2.0 |
| Management | 3.0 |
| Valuation | 6.0 |
| Risk · 10 = lowest | 4.0 |
| Business model | 4.0 |
| Optionality | 6.0 |
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.
Start the thirty days · no card